SOLVE-CRT study metits primary safety and efficacy endpoints for the WiSE CRT System technologywhich is associated with a reduction in LVESV in heart failure patients.
EBR
Posted on
July 31, 2024
EBR's pivotal SOLVE-CRT Study published in JAMA Cardiology
The SOLVE-CRT trial evaluated patients indicated for CRT who were previously untreatable or considered high risk upgrades. The study found that the WiSE CRT System, the only leadless left ventricular endocardial pacing (LVEP) device, can safely deliver CRT.16.4% improvement in left ventricular end systolic volume (LVESV), in heart failure patients in the first 6-months80.9% of patients had no serious procedure or device-related complications in the first 6-months